1. Home
  2. TRDA vs BLUW Comparison

TRDA vs BLUW Comparison

Compare TRDA & BLUW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$10.88

Market Cap

404.4M

Sector

Health Care

ML Signal

HOLD

BLUW

Blue Water Acquisition Corp. III Class A Ordinary Shares

N/A

Current Price

$10.35

Market Cap

325.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
TRDA
BLUW
Founded
2016
2024
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
404.4M
325.0M
IPO Year
2021
2025

Fundamental Metrics

Financial Performance
Metric
TRDA
BLUW
Price
$10.88
$10.35
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$20.00
N/A
AVG Volume (30 Days)
246.9K
52.5K
Earning Date
03-06-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$61,520,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$21.02
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.93
$9.93
52 Week High
$13.82
$10.41

Technical Indicators

Market Signals
Indicator
TRDA
BLUW
Relative Strength Index (RSI) 52.05 60.95
Support Level $10.48 $10.25
Resistance Level $11.41 $10.39
Average True Range (ATR) 0.74 0.03
MACD -0.06 -0.00
Stochastic Oscillator 54.08 75.00

Price Performance

Historical Comparison
TRDA
BLUW

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

About BLUW Blue Water Acquisition Corp. III Class A Ordinary Shares

Blue Water Acquisition Corp III is a blank check company.

Share on Social Networks: